CryoLife Inc. engages in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. The company was founded in 1984 and is based in Kennesaw, Georgia.
CRY Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for CRY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cryolife Inc ranked in the 13th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.83%. As for the metrics that stood out in our discounted cash flow analysis of Cryolife Inc, consider:
Cryolife Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 10. This value is greater than 84.41% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
QGEN, DYNT, IDXX, LCTC, and RGEN can be thought of as valuation peers to CRY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
CryoLife (CRY) has priced $100M aggregate principal amount of 4.250% convertible senior notes due 2025 in a private placement.Initial purchasers are granted an option to purchase up to an additional $15M of the Notes. The initial conversion rate is 42.6203 shares per $1,000 principal amount of Notes (~$23.46/share).Net proceeds of ~$96.5M...
ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025…
CryoLife (CRY) intends to offer $100M aggregate principal amount of convertible senior notes due 2025 in a private placement.Initial purchasers will have an option to purchase up to an additional $15M of the Notes. The interest rate, initial conversion rate, and other terms of the Notes are not yet determined....
ATLANTA , June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY ) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $15,000,000 aggregate principal amount of the Notes. The Notes will be senior unsecured...
A full 100 days since the official start of the coronavirus pandemic and the U.S. death toll is approaching 118,000, with new cases still climbing in 20 states, even as governors push to reopen more businesses.